Lundbeck, Otsuka Pharmaceutical deal

Lundbeck granted Otsuka co-development and co-commercialization rights to Lu AE58054 in the U.S., Canada, East Asia, major European countries and Nordic countries. The selective serotonin (5-HT6) receptor antagonist is in Phase II testing for Alzheimer's disease (AD), with a Phase III program slated to start this year. Lundbeck will receive $150 million up front and is eligible for up to $675 million in milestones. The companies will share development and commercialization costs. ...